Innovative and adaptive strategies for new drug development are needed to maximize the potential of cell and gene therapies. CRA’s Lev Gerlovin with co-authors Walter Colasante and Pascale Diesel explain in this Cell and Gene article. Click here to read the article.
The end of high drug prices? Exploring the potential and limits of PDABs
Certain states in the US have enacted or are actively considering legislation to create PDABs, Prescription Drug Affordability Boards. PDABs are independent...